SYSTEMIC LUPUS ERYTHEMATOSUS
The
overall prevalence of SLE is estimated to be 100 per 100,000 persons. It occurs
10 times more frequently in women than in men and approximately three times
more frequently in the African-American population than in Caucasians (Ruddy et
al., 2001).
SLE
is a result of disturbed immune regulation that causes an exaggerated
production of autoantibodies. This immuno-regulatory disturbance is brought
about by some combination of genetic, hormonal (as evidenced by the usual onset
during the childbearing years), and environmental factors (sunlight, thermal
burns). Certain medications, such as hydralazine (Apresoline), procainamide
(Pronestyl), isoniazid (INH), chlorpromazine (Thorazine), and some antiseizure
medications, have been impli-cated in chemical or drug-induced SLE.
In
SLE, the increase in autoantibody production is thought to result from abnormal
suppressor T-cell function, leading to im-mune complex deposition and tissue
damage. Inflammation stim-ulates antigens, which in turn stimulate additional
antibodies, and the cycle repeats.
The
onset of SLE may be insidious or acute. For this reason, SLE may remain
undiagnosed for many years. Clinical features of SLE involve multiple body systems.
SLE is an autoimmune systemic disease that can
affect any body system. Involvement of the musculoskeletal system, with
arthral-gias and arthritis (synovitis), is a common presenting feature of SLE.
Joint swelling, tenderness, and pain on movement are also common. Frequently,
these are accompanied by morning stiffness.
Several different types of skin manifestations may occur in pa-tients with SLE, including subacute cutaneous lupus erythe-matosus, which involves papulosquamous or annular polycyclic lesions, and discoid lupus erythematosus, which is a chronic rash that has erythematous papules or plaques and scaling and can cause scarring and pigmentation changes. The most familiar skin manifestation (but occurring in fewer than half of patients with SLE) is an acute cutaneous lesion consisting of a butterfly-shaped rash across the bridge of the nose and cheeks (Fig. 54-5). In some cases of discoid lupus erythematosus, only skin involvement may occur. In some SLE patients, the initial skin involvement may be the precursor to more systemic involvement.
The lesions often worsen during
exacerbations (flares) of the systemic disease and possibly are provoked by
sunlight or artificial ultraviolet light. Oral ulcers, which may accompany skin
lesions, may involve the buccal mucosa or the hard palate. The ulcers occur in
crops and are often associated with exacerbations.
Pericarditis
is the most common cardiac manifestation. Women who have SLE are also at risk
for early atherosclerosis.
Serum
creatinine levels and urinalysis are used in screening for renal involvement.
Early detection allows for prompt treatment so that renal damage can be
prevented. Renal involvement may lead to hypertension, which also requires
careful monitoring and management.
Central nervous system involvement is widespread,
encom-passing the entire range of neurologic disease. The varied and fre-quent
neuropsychiatric presentations of SLE are now widely recognized. These are
generally demonstrated by subtle changes in behavior patterns or cognitive
ability. Depression and psychosis are common (Klippel, 2001; Petri, 2000; Ruddy
et al., 2001).
Diagnosis
of SLE is based on a complete history, physical exam-ination, and blood tests.
In addition to the general assessment performed for any patient with a
rheumatic disease, assessment for known or suspected SLE has special features.
The skin is inspected for erythematous rashes. Cutaneous erythematous plaques
with an adherent scale may be observed on the scalp, face, or neck. Areas of
hyperpigmentation or depigmentation may be noted, depending on the phase and
type of the disease. The pa-tient should be questioned about skin changes
(because these may be transitory) and specifically about sensitivity to
sunlight or arti-ficial ultraviolet light. The scalp should be inspected for
alopecia and the mouth and throat for ulcerations reflecting gastrointesti-nal
involvement.
Cardiovascular
assessment includes auscultation for peri-cardial friction rub, possibly
associated with myocarditis and accompanying pleural effusions. The pleural
effusions and infil-trations, which reflect respiratory insufficiency, are
demonstrated by abnormal lung sounds. Papular, erythematous, and purpuric
lesions developing on the fingertips, elbows, toes, and extensor surfaces of
the forearms or lateral sides of the hand that may be-come necrotic suggest
vascular involvement.
Joint
swelling, tenderness, warmth, pain on movement, stiff-ness, and edema may be
detected on physical examination. The joint involvement is often symmetric and
similar to that found in RA.
Typically,
assessment reveals classic symptoms, including fever, fatigue, and weight loss
and possibly arthritis, pleurisy, and peri-carditis. Interactions with the
patient and family may provide further evidence of systemic involvement. The
neurologic as-sessment is directed at identifying and describing any central
nervous system changes. The patient and family members are asked about any
behavioral changes, including manifestations of neuroses or psychosis. Signs of
depression are noted, as are reports of seizures, chorea, or other central
nervous system manifestations.
No
single laboratory test confirms SLE; rather, blood testing reveals moderate to
severe anemia, thrombocytopenia, leukocy-tosis, or leukopenia and positive
antinuclear antibodies. Other diagnostic immunologic tests support but do not
confirm the diagnosis. Hematuria may be found on urinalysis.
Treatment
of SLE includes management of acute and chronic disease. Although SLE can be
life-threatening, advances in its treatment have led to improved survival and
reduced morbidity. Acute disease requires interventions directed at controlling
in-creased disease activity or exacerbations that may involve any organ system.
Disease activity is a composite of clinical and lab-oratory features that
reflect active inflammation secondary to SLE. Management of the more chronic
condition involves peri-odic monitoring and recognition of meaningful clinical
changes requiring adjustments in therapy (Ruddy et al., 2001).
The
goals of treatment include preventing progressive loss of organ function,
reducing the likelihood of acute disease, mini-mizing disease-related
disabilities, and preventing complications from therapy. Management of SLE
involves regular monitoring to assess disease activity and therapeutic
effectiveness.
Medication therapy for SLE is based on the concept
that local tis-sue inflammation is mediated by exaggerated or heightened
im-mune responses, which can vary widely in intensity and require different
therapies at different times. The NSAIDs used for minor clinical manifestations
are often used along with cortico-steroids in an effort to minimize
corticosteroid requirements.
Corticosteroids are the single most important
medication available for treatment. They are used topically for cutaneous
manifestations, in low oral doses for minor disease activity, and in high doses
for major disease activity. Intravenous administra-tion of corticosteroids is
an alternative to traditional high-dose oral use. Antimalarial medications are
effective for managing cu-taneous, musculoskeletal, and mild systemic features
of SLE. Immunosuppressive agents (alkylating agents and purine analogs) are
used because of their effect on immune function. These med-ications are
generally reserved for patients who have serious forms of SLE and who have not
responded to conservative therapies (Kimberly, 2001; National Institutes of
Health, 1998; Ruddy et al., 2001).
The nursing care of the patient with SLE is based
on the basic plan presented earlier. The most common prob-lems include fatigue,
impaired skin integrity, body image distur-bance, and lack of knowledge for
self-management decisions. The disease or its treatment may produce dramatic
changes in ap-pearance and considerable distress for the patient. The changes
and the unpredictable course of SLE necessitate expert assessment skills and
nursing care and sensitivity to the psychological re-actions of the patient.
Patients may benefit from participation in support groups by receiving disease
information, daily manage-ment tips, and social support. Because sun and
ultraviolet light exposure can increase disease activity or cause an
exacerbation, patients should be taught to avoid exposure or to protect
them-selves with sunscreen and clothing.
Because
of the increased risk for involvement of multiple organ systems, patients
should understand the need for routine periodic screenings as well as health
promotion activities. A di-etary consultation may be indicated to ensure that
the patient is knowledgeable about dietary recommendations, given the
in-creased risk for cardiovascular disease, including hypertension and
atherosclerosis. The nurse instructs the patient about the im-portance of
continuing prescribed medications and addresses the changes and side effects
that are likely with their use. The patient is reminded of the importance of monitoring
because of the in-creased risk for systemic involvement, including renal and
cardio-vascular effects.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.